Gracell Biotechnology
Latest round
- Series C
Last raised
- Oct 2020
Total raised
- $206M
Investors
- 11
About Gracell Biotechnology
Gracell Biotechnology Ltd.Founded in 2017 in Shanghai, China, Gracell Biotechnology Ltd. specializes in advanced cell therapies. The company has undergone strategic developments, including a significant transition to public ownership. Wei Cao serves as both Founder and CEO.Gracell develops innovative cell therapies addressing challenges in cancer and autoimmune diseases. Key offerings include the FasTCAR platform for rapid manufacturing of CAR-T cells, the TruUCART platform for off-the-shelf CAR-T therapies, and the SMART CART technology targeting solid tumors.30.Gracell Biotechnology Ltd. plans to launch new products and expand its market presence. The company aims to broaden its reach into additional markets by targeting specific regions in North America and Europe, leveraging its innovative therapies to enhance patient access by the end of 2023.
Who invested in Gracell Biotechnology
11 investors across 5 rounds
See all investors in Gracell Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Gracell Biotechnology
Who invested in Gracell Biotechnology?
Gracell Biotechnology has 11 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gracell Biotechnology raised?
Gracell Biotechnology has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Gracell Biotechnology last raise money?
Gracell Biotechnology's most recent round on record is a Series C, in Oct 2020.
What does Gracell Biotechnology do?
Gracell Biotechnology is a biotechnology company.
Where is Gracell Biotechnology headquartered?
Gracell Biotechnology is headquartered in Shanghai, China.
Which VCs invest in companies like Gracell Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Gracell Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Gracell Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.